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Abstract
Urinary bladder cancer is the one of the most common cancers affecting the Western 
world.  In addition, bladder cancer is considered one of the most expensive cancers to 
treat due to the necessary surveillance and treatment of recurrences.  There is a need 
for more effective and less toxic treatment strategies as well as potential preventative 
options.  Recently a novel derivative of indole-3-carbinol has been designed and shown 
to be significantly more potent at inhibiting cancer in vitro than the natural parent 
compound in liver, prostate and breast models.  This derivative, named OSU-A9, shows 
promise for becoming a new and effective drug for the treatment of bladder cancer.   In 
vitro effects of I3C and OSU-A9 were studied in both a non-invasive (RT4) and invasive 
(UMUC3) bladder cancer cell lines.  Treatment with I3C and OSU-A9 exhibited dose 
and time dependent inhibitory effects on the viability of both superficial (RT4) and the 
invasive (UMUC3) cell lines.  In both RT4 cells and UMUC3 cells, OSU-A9 was greater 
than 100-fold more potent than I3C. In UMUC3 cells, treatment with OSU-A9 caused a 
does-dependent change in the percentage of the cell population in G2 phase. To 
evaluate the in vivo efficacy of I3C and OSU-A9, female nude mice were 
subcutaneously injected with 100,000 UMUC3 cells in the bilateral flanks.  Our 
preliminary in vivo data indicates that, compared to controls, animals treated with I3C 
and OSU-A9, both at 25 mg/kg, show reduced tumor weight by 49% and 26% 
respectively and reduced tumor volume by 61% and 31% respectively.  OSU-A9 
exhibits more potent anti-cancer activity than the natural parent compound, I3C, in vitro 
for both superficial and invasive bladder cancer.  OSU-A9 and I3C inhibited the 
progression of tumors in preliminary in vivo models of invasive bladder cancer.  Further 
studies are warranted to investigate the mechanisms by which OSU-A9 exhibits anti-
cancer activity and its potential for bladder cancer prevention in pre-clinical models.  In 
summary, both the natural compound, I3C, and its derivative, OSU-A9, show promise 
for being effective treatments for both superficial and invasive bladder cancer.
Introduction
Urothelial carcinoma is one of the most common cancers in the world, ranking fifth in 
the Western world (1).  Most epithelial tumors are believed to progress along a single 
pathway; urothelial carcinomas have been found to arise through two separate 
mechanisms each with considerably different behaviors and prognoses (2).  Low-grade 
non-invasive superficial papillary urothelial carcinomas are thought to arise from simple 
urothelial hyperplasia.  These tumors make up about 80% of diagnosed bladder cancers 
and are easily treatable through surgery and immunotherapy, with a 5-year survival rate 
of 90%.  However, they have a high rate of recurrence and require multiple surgical 
resections.  The other main type, accounting for about 20% of bladder cancers, is 
invasive and occurs in patients with no previous history of low-grade papillary tumors.  
These tumors arise de novo or from flat, high-grade carcinoma in situ (CIS) lesions.  
Despite therapy, at least half of patients with these invasive tumors die from metastases 
within 2 years of diagnosis (3).  The five-year survival rate for patients with advanced 
bladder cancer is only 6% with treatment failing in 95% of patients.  Factors that have 
been linked to urothelial tumors include tobacco smoking, exposure to aromatic amines, 
drinking water laced with arsenic, chronic infection with Schistosoma species, radiation 
therapy, and therapeutic use of alkylating agents (4).
Diet and food intake has long been hypothesized to have a relationship with cancer risk 
and prevention.  Though many epidemiological studies of fruit and vegetable intake and 
bladder cancer risk have been conducted, it was not until the Health Professionals 
Follow-up Study that strong evidence was found between food intake and decreased 
risk of bladder cancer.  Results of this study demonstrated a weak, inverse association 
between total fruit and vegetable intake and bladder cancer risk, but it was not 
statistically significant (5).  In the breakdown of each individual food group, cruciferous 
vegetables (except for coleslaw) all showed inverse relations between bladder cancer 
and intake, however only increased broccoli and cabbage intake showed a statistically 
significant decrease in risk of bladder cancer.
There have been several studies to identify the phytochemicals found in cruciferous 
vegetables which convey this cancer prevention activity.  One compound discovered, 
glucobrassicin, has been found to inhibit multiple cancers, including lung and stomach 
cancers in mice and breast cancer in rat  (6).  When glucobrassicin is hydrolyzed, it 
gives rise to a number of indole compounds.  Indole-3-carbinol (I3C) is one of these 
metabolites which has shown anti-carcinogenic activity in breast and ovarian cancers 
(7, 8). More recent studies have shown that I3C induces growth arrest and apoptosis by 
targeting several cell cycle signaling pathways, including those mediated by Akt, nuclear 
factor-κB (NF-κB), Bcl-2, mitogen-activated protein (MAP) kinases, the cyclin-
dependent kinase (CDK) inhibitors p21 and p27, and cyclin D1 (9-13).
OSU-A9 is a novel compound developed to exploit the antitumor properties of I3C.  It is 
more stable than the natural compound as it does not form acid-catalyzed condensation 
products as I3C does (14, 15).  Besides improved structural stability, OSU-A9 has 
shown to have 100 fold higher 
apoptosis-inducing activity than I3C in
prostate, breast, and liver cancers both 
in vitro and in vivo with very little toxicity 
to healthy cells (15-17).
In these previous studies, I3C and OSU-A9 have been proven to have antitumorigenic 
activity and have the potential to become effective treatments for many cancers. 
Therefore, we aimed to compare the ability of I3C and OSU-A9 to inhibit the growth of 
superficial and invasive bladder cancer cells in vitro and of invasive bladder cancer cells 
in an in vivo xenograft model.   
Materials and Methods
Reagents: Indole-3 Carbinol was obtained from Sigma-Aldrich (St. Louis, MO) and 
OSU-A9 was provided by Dr. Ching-Shih Chen of The Ohio State University College of 
Pharmacy.  I3C and OSU-A9 were dissolved in dimethyl sulfoxide (DMSO; Sigma-
Aldrich, St. Louis, MO) prior to use.  
Figure 1.  Chemical structures of the natural 
parent compound I3C and the novel derivative.
Cell Culture:  RT4 and UMUC3 bladder cancer cell lines were purchased from the 
American Type Culture Collection (ATCC; Manassas, VA).  Cells were maintained as 
monolayer cultures in RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented 
with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 2mM L-glutamine, and 
antibiotic-antimycotic (GIBCO, Grand Island, NY) at 37 °C in a 5% CO2 / 95% air, 
humidified atmosphere.  Cells were seeded, grown for 24h and then treated with I3C, 
OSU-A9 or control for 24, 48 or 72 h as reported for each experiment.
Cell Viability: Cells were seeded in 96-well plates, grown for 24h, and treated with 
culture medium containing I3C, OSU-A9, or vehicle in 0.1% DMSO for 24, 48 or 72h.
Cell viability was measured by the SRB assay (In Vitro Toxicology Assay Kit, Sigma-
Aldrich, St. Louis, MO) using a HTS 7000 BioAssay reader (Perkin Elmer, Norwalk, CT) 
at an absorbance wavelength of 565 nm.
Cell Cycle:  Cells were seeded in plates, grown for 24h and treated with culture 
medium containing I3C, OSU-A9, or vehicle, for 24 and 48 h.  Cultures were harvested 
and fixed in 70% ethanol, -200C, for at least 2 h. Cells were then treated with PBS 
containing, 0.1% Triton -X100, Propidium Iodide (50 µg/ml), RNase A (200 µg / ml) for
30 min at room temperature. Cell cycle analysis was conducted using the FACSCalibur 
flow cytometer (Beckton Dickinson, San Jose, CA) and data were analyzed with ModFit 
software (Verity Software House Inc. Topsham, Maine). 
In vivo study: Female athymic nude FOXN1nu mice (4-5 week old) were purchased 
from Harlan Sprague Dawley (Indianapolis, IN). The mice were group-housed under 
alternating 12 hours light and dark cycle, with ad libitum access to sterile food and 
water. Each mouse was injected s.c. with 1 x 105 UMUC3 cells, in two flanks, in a total 
volume of 0.2ml serum free RPMI1640 containing 50% Matrigel (BD Biosciences, 
Bedford, MA). The animals were then randomly assigned to treatment with I3C (n=3), 
OSU-A9 (n=5) or control (n=4) groups.  Three days after injection, mice began 
treatment, by daily gavage with either I3C (25 mg/kg body weight), OSU-A9 (25 mg/kg 
body weight) or vehicle (1% DMSO in soybean oil).  Body weights and tumors were 
measured twice weekly. Tumor volumes were estimated using caliper measurements 
and using the standard formula: width2 x length x 0.52 (18). Mice were euthanized 
before the tumors in any animal reached the maximum allowable tumor burden of a 
diameter of 1.2 cm.  Tumor and organ (bladder, spleen, liver, kidney) weights were 
measured at necropsy. About half of each tumor and organ was fixed in formalin for 
histological studies, one quarter snap frozen in liquid N2 for protein analysis, and one 
quarter stored in RNAlater Solution (Ambion, Austin, TX) overnight at 40C for RNA 
analysis. All experimental procedures using the mice were in accordance with protocols 
approved by the Institutional Laboratory Animal Care and Use Committee of The Ohio 
State University.
Statistics: Cell culture-based assays were repeated three times with mean ± SD 
calculated. Cell lines were examined separately. Outcomes measured at a single time 
point were analyzed by two-sample t-tests to assess differences between groups. 
Differences in xenograft tumor growth were assessed using a two-tailed Student’s t-test. 
Significance was set at p ≤ 0.05.
Results
OSU-A9 inhibits cell viability of human bladder cancer cells time and dose 
dependently with higher potency relative to I3C
The effects of indole-3-carbinol and OSU-A9 were evaluated in superficial (RT4) and 
invasive (UMUC3) human bladder cancer cells.  Cells were treated with concentrations 
of I3C and OSU-A9 from 1-1000 µM or DMSO control for 24, 48 and 72 hours.  For 
each treatment time, there was a dose-dependent inhibition of both cell lines with OSU-
A9 being approximately 100X more potent than I3C.  After 48 hours of treatment, OSU-
A9 had an IC50=2.4 µM and IC50<1 µM for RT4 and UMUC3 cells respectively.  The 
same treatment time with I3C resulted in IC50=280 µM for RT4 cells and IC50=150 µM
for UMUC3 cells.   Both I3C and OSU-A9 also caused a time-dependent inhibition of 
viability of RT4 and UMUC3 cells when treated with the same concentration of drug 
over 24, 48 and 72 hours.  Interestingly, the invasive UMUC3 cells were more 
susceptible to treatment with both compounds with OSU-A9 having a much lower IC50 in 
UMUC3 cells than in RT4 cells.  These studies indicate that OSU-A9 and I3C are both 
inhibitors of human bladder cancer cell lines with OSU-A9 having much greater potency 
and that invasive human urothelial cancer cells are more sensitive to the inhibitory 
effects of these compounds compared to superficial cancer cells.
Human bladder cancer cells treated with OSU-A9 exhibit markers of cell death
and a significant accumulation of UMUC3 cells in G2 phase occurs
In order to determine the effects of these compounds cell cycle progression and 
apoptosis, RT4 and UMUC3 cells were treated with I3C (200, 400 and 600 µM) and 
OSU-A9 (1, 5 and 10 µM) or DMSO control for 24 and 48 hours.  Cells were fixed and 
stained with propidium iodide (PI) which intercalates with DNA.  The PI staining intensity
corresponds to cellular DNA content which is an indication of the phase in the cell cycle.  
The cell population was viewed by Forward Side Scatter (FSC), a measure of cell size
Figure 2.  Percentage of viable UMUC3 and 
RT4 cells remaining after treatment with I3C 
(1-1000 μM) and OSU-A9 (1-1000 μM) for 
24, 48 and 72 h.  After 48 h of treatment, 
OSU-A9 had an IC50=2.4 μM for RT4 and 
IC50<1 μM for UMUC3.  I3C had an 
IC50=280 μM for RT4 and IC50=150 μM for 
UMUC3 cells.  OSU-A9 shows higher 
potency in the invasive UMUC3 cells and 
has 100x greater efficacy for both cell lines 
compared to I3C.
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and an indication of cell death.  For both UMUC3 and RT4 cells treated with OSU-A9, 
there was a does-dependent decrease in the size of the cells in the population. This 
was not seen in cells treated with I3C.  Because of the large amount of cell debris in the 
samples, debris had to be removed by the software before ModFit could accurately 
model the proportion of cells in each phase of the cell cycle.  After removing debris, 
modeling showed that UMUC3 cells treated with OSU-A9 at 5 and 10 µM for 24 hours 
and 10 µM for 48 hours had a significant accumulation in G2 phase (p<0.05).  Cells 
treated with I3C had no significant changes in their cell cycles.
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Control
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Figure 3.  (A) ModFit cell cycle analysis after treatment of 24 h.  Treatment of UMUC3 cells with 
OSU-A9 at 5 and 10 μM causes an accumulation of cells in G2 phase (p<0.05).  This effect 
was not observed in UMUC3 cells treated with I3C nor in RT4 cells treated with either OSU-
A9 or I3C.  Cell debris in the sub-G0/G1 range was not included in order for ModFit to model 
cell cycle more accurately.  (B)  Cell size, visualized by Forward Side Scatter (FSC) using 
FlowJo, decreased in UMUC3 and RT4 cells after treatment with OSU-A9. This is an 
indication of cell death and mechanisms of apoptosis.  
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UMUC3 xenograft tumor growth is significantly inhibited by indole-3-carbinol
We wanted to assess the translation of our in vitro findings in an in vivo mouse model. 
We utilized a subcutaneous xenograft tumor model in athymic nude mice, injected with 
UMUC3 invasive human bladder cancer cells.  Starting three days after cells were 
injected, mice were treated daily by gavage with either I3C (25 mg/kg body weight), 
OSU-A9 (25 mg/kg body weight) or vehicle (1% DMSO in soybean oil) for 2.5 weeks.   
Mice were euthanized when tumors reached the maximum diameter of 1.2 cm.  There 
was no evidence of toxicity in any animal treated with I3C or OSU-A9.  Animals 
administered with I3C and OSU-A9 had decreased tumor progression over time
compared to animals administered with vehicle.  Mean tumor volumes after necropsy for 
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Figure 4.  (A) UMUC3 xenograft tumor growth 
in animals gavaged daily with OSU-A9 (25 
mg/kg body weight) and I3C (25 mg/kg body 
weight) both limited tumor growth compared to 
tumors on mice treated with DMSO vehicle.  
(B)  Tumor weights measured after necropsy.  
Both OSU-A9 and I3C inhibited tumor 
progression compared to DMSO vehicle. I3C 
was more effective than OSU-A9 (asterisk 
indicates p<0.05).  (C) Tumor volumes 
measured after necropsy.  Results are similar 
to tumor weight (asterisk indicates p<0.05).  
Histopathological evaluation of tumor samples 
is currently underway.
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animals treated with I3C were 61% smaller and tumor weights were 49% less compared 
to the control mice.  While tumor weights and volumes for I3C treated animals were 
significantly smaller (p<0.05), OSU-A9 treated animals also had mean tumor volumes 
31% smaller and tumor weights 26% less than control mice tumors (not significant).
Discussion
There is an obvious need for the development of new and effective drugs with increased 
potency for both bladder cancer treatment and prevention.  Nature has already provided 
numerous compounds and structures which have been proven to have anticarcinogenic 
properties.  By using naturally occurring compounds and novel derivatives based upon 
their structure, bladder cancer prevention and treatment can be accomplished in pre-
clinical models.  We show that modifying a natural compound with notable anti-cancer 
activity in vitro can result in new drugs with greatly increased potency.  While I3C has a 
relatively high IC50=280 µM for superficial RT4 bladder cancer cells and IC50=150 µM for 
invasive UMUC3 cells, the novel derivative greatly reduces cell viability to IC50=2.4 µM
and IC50<1 µM for RT4 and UMUC3 cells respectively.  
Investigations into the mechanisms of cell death began with the cell cycle studies 
above.  OSU-A9 causes significant cell death in both UMUC3 and RT4 cells and a 
dramatic shift in the cell size of the population.  Also when treated with higher 
concentrations of OSU-A9, UMUC3 cells have a significant accumulation in G2.  Cells 
treated with I3C did not exhibit any significant changes in cell cycle.  It is possible that 
because both compounds cause such high cell death, they are in fact impacting the cell 
cycle at earlier time points.  Additional studies are underway to investigate the impact 
on cell cycle and apoptosis at much earlier treatment times (6 or 12 hours).  In addition, 
we will confirm cell death is occurring through apoptosis using additional analyses 
including western blotting for caspase 3/7 and other markers of apoptosis.  Further 
western blotting of cell cycle markers involved in cell death and survival such as the NF-
kB and Akt pathways will be investigated.
The most surprising results of these studies are the effects of the natural parent 
compound, I3C, in vivo.  The in vitro viability data indicated that OSU-A9 would also be 
much more potent than I3C in vivo.  While OSU-A9 does tend to inhibit UMUC3 
xenograft tumor progression, I3C at the same concentration is significantly more 
bioactive.  I3C shows surprising in vivo activity suggesting important differences in 
bioavailability.   Tumor samples remain to be analyzed for histopathology and additional 
biomarkers for the mechanism of action including proliferation and apoptosis.  However
based upon mean tumor volume and weights I3C is a more effective anti-tumorogenesis 
agent.  I3C shows surprising in vivo activity suggesting that metabolic activation may be 
necessary for bioactivity.  In order to better understand this phenomenon, studies on the 
absorption and metabolism of I3C and OSU-A9 remains to be conducted.  This model 
only tested the chemotherapeutic ability of I3C and OSU-A9 but does not specifically 
test bladder cancer prevention.  A model of carcinogenesis where treatment starts 
before tumors develop can better test preventative capabilities of these compounds (19, 
20).
Taking both the in vitro and in vivo studies into account, we cannot yet paint a complete 
picture of the ability of these compounds to treat bladder cancer.  It is clear that the 
novel compound OSU-A9 is capable of greatly increased cell death to human bladder 
cancer cells in vitro but the results of the xenograft study show that we cannot rule out 
the antitumorogenesis capabilities of the natural parent compound indole-3-carbinol.  
Our studies have shown that while OSU-A9 could be used as an effective treatment, we 
must consider I3C as having equal, if not greater potency in vivo.  Further studies are 
warranted into both discovering the full potential of the new derivative, OSU-A9, and 
reinvestigating the abilities of the natural parent, I3C.
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